收费全文 | 4665篇 |
免费 | 471篇 |
5136篇 |
2022年 | 34篇 |
2021年 | 55篇 |
2020年 | 44篇 |
2019年 | 55篇 |
2018年 | 56篇 |
2017年 | 80篇 |
2016年 | 88篇 |
2015年 | 149篇 |
2014年 | 190篇 |
2013年 | 203篇 |
2012年 | 276篇 |
2011年 | 257篇 |
2010年 | 181篇 |
2009年 | 169篇 |
2008年 | 229篇 |
2007年 | 205篇 |
2006年 | 190篇 |
2005年 | 204篇 |
2004年 | 212篇 |
2003年 | 202篇 |
2002年 | 166篇 |
2001年 | 180篇 |
2000年 | 149篇 |
1999年 | 145篇 |
1998年 | 82篇 |
1997年 | 81篇 |
1996年 | 61篇 |
1995年 | 45篇 |
1994年 | 65篇 |
1993年 | 45篇 |
1992年 | 86篇 |
1991年 | 73篇 |
1990年 | 73篇 |
1989年 | 71篇 |
1988年 | 57篇 |
1987年 | 41篇 |
1986年 | 40篇 |
1985年 | 67篇 |
1984年 | 43篇 |
1983年 | 35篇 |
1982年 | 40篇 |
1981年 | 26篇 |
1980年 | 25篇 |
1979年 | 42篇 |
1978年 | 23篇 |
1977年 | 23篇 |
1976年 | 24篇 |
1974年 | 29篇 |
1973年 | 24篇 |
1972年 | 22篇 |
Purpose
We tested the hypothesis that expression of microRNAs (miRNAs) in cancer tissue can predict effectiveness of bevacizumab added to capecitabine and oxaliplatin (CAPEOX) in patients with metastatic colorectal cancer (mCRC).Experimental Design
Patients with mCRC treated with first line CAPEOX and bevacizumab (CAPEOXBEV): screening (n = 212) and validation (n = 121) cohorts, or CAPEOX alone: control cohort (n = 127), were identified retrospectively and archival primary tumor samples were collected. Expression of 754 miRNAs was analyzed in the screening cohort using polymerase chain reaction (PCR) arrays and expression levels were related to time to disease progression (TTP) and overall survival (OS). Significant miRNAs from the screening study were analyzed in all three cohorts using custom PCR arrays. In situ hybridization (ISH) was done for selected miRNAs.Results
In the screening study, 26 miRNAs were significantly correlated with outcome in multivariate analyses. Twenty-two miRNAs were selected for further study. Higher miR-664-3p expression and lower miR-455-5p expression were predictive of improved outcome in the CAPEOXBEV cohorts and showed a significant interaction with bevacizumab effectiveness. The effects were strongest for OS. Both miRNAs showed high expression in stromal cells. Higher expression of miR-196b-5p and miR-592 predicted improved outcome regardless of bevacizumab treatment, with similar effect estimates in all three cohorts.Conclusions
We have identified potentially predictive miRNAs for bevacizumab effectiveness and additional miRNAs that could be related to chemotherapy effectiveness or prognosis in patients with mCRC. Our findings need further validation in large cohorts, preferably from completed randomized trials. 相似文献Methods: Single-center sub-study of 171 patients included in the Target Temperature Management (TTM) Trial randomly assigned to TTM at 33?°C or TTM at 36?°C for 24?h after OHCA. Fragments (tau-A and tau-C) of the neuronal protein tau were measured in serum 24, 48 and 72?h after OHCA. The primary endpoint was neurological outcome.
Results: Median (quartile 1 – quartile 3) tau-A (ng/ml) values were 58 (43–71) versus 51 (43–67), 72 (57–84) versus 71 (59–82) and 76 (61–92) versus 75 (64–89) for good versus unfavourable outcome at 24, 48 and 72?h, respectively (pgroup = 0.95). Median tau C (ng/ml) values were 38 (29–50) versus 36 (29–49), 49 (38–58) versus 48 (33–59) and 48 (39–59) versus 48 (36–62) (pgroup = 0.95). Tau-A and tau-C did not predict neurological outcome (area under the receiver-operating curve at 48?h; tau-A: 0.51 and tau-C: 0.51).
Conclusions: Serum levels of tau fragments were unable to predict neurological outcome after OHCA. 相似文献